Current status and treatment strategy of neoadjuvant chemotherapy for pancreatic cancer

doi:10.3877/cma.j.issn.2095-3232.2024.05.009

Abstract

Abstract:

Surgical resection of the primary lesion combined with systemic chemotherapy is the optimal treatment for pancreatic ductal adenocarcinoma (PDAC). Combined treatment can yield longer overall survival (OS). Most patients recur due to postoperative micrometastasis, and neoadjuvant chemotherapy can improve OS. Approximately 20% of patients with unresectable PDAC might undergo resection after 4-6 month induction therapy combined with chemotherapy, thereby improving the OS. We described current treatment strategies for PDAC in different clinical stages, aiming to provide a reference for enhancing the overall treatment level for pancreatic cancer in China.

Key words: Pancreatic neoplasms, Pancreatic ductal adenocarcinoma, Neoadjuvant chemotherapy, Treatment

Junhua Wang, Ruixuan Wang. Current status and treatment strategy of neoadjuvant chemotherapy for pancreatic cancer[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 640-643.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2024.05.009

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2024/V13/I05/640

References 28

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1):7-30.
[2]	Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer[J]. Nat Rev Clin Oncol, 2020, 17(2):108-123.
[3]	Strobel O, Neoptolemos J, Jäger D, et al. Optimizing the outcomes of pancreatic cancer surgery[J]. Nat Rev Clin Oncol, 2019, 16(1):11-26.
[4]	Hu Q, Wang D, Chen Y, et al. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma[J]. Radiat Oncol, 2019, 14(1):120.
[5]	Park W, Chawla A, O'Reilly EM. Pancreatic cancer: a review[J]. JAMA, 2021, 326(9):851-862.
[6]	Klaiber U, Hackert T, Neoptolemos JP. Adjuvant treatment for pancreatic cancer[J]. Transl Gastroenterol Hepatol, 2019, 4:27.
[7]	Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer[J]. N Engl J Med, 2004, 350(12):1200-1210.
[8]	Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial[J]. JAMA, 2010, 304(10):1073-1081.
[9]	Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial[J]. JAMA, 2013, 310(14):1473-1481.
[10]	Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4):a multicentre, open-label, randomised, phase 3 trial[J]. Lancet, 2017, 389(10073):1011-1024.
[11]	Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer[J]. N Engl J Med, 2018, 379(25):2395-2406.
[12]	Frei E 3rd. Clinical cancer research: an embattled species[J]. Cancer, 1982, 50(10):1979-1992.
[13]	Seufferlein T, Uhl W, Kornmann M, et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phaseⅡtrial of the AIO pancreatic cancer group[J]. Ann Oncol, 2023, 34(1):91-100.
[14]	Ghaneh P, Palmer D, Cicconi S, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2023, 8(2):157-168.
[15]	Katz MH, Shi Q, Ahmad SA, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101[J]. JAMA Surg, 2016, 151(8):e161137.
[16]	国家卫生健康委员会办公厅. 胰腺癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(5):1006-1030.
[17]	Nakao A, Kanzaki A, Fujii T, et al. Correlation between radiographic classification and pathological grade of portal vein wall invasion in pancreatic head cancer[J]. Ann Surg, 2012, 255(1):103-108.
[18]	Groot VP, Rezaee N, Wu W, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma[J]. Ann Surg, 2018, 267(5):936-945.
[19]	Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase Ⅲ PREOPANC trial[J]. J Clin Oncol, 2020, 38(16):1763-1773.
[20]	Motoi F, Satoi S, Honda G, et al. A single-arm, phase Ⅱ trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: prep-01 study[J]. J Gastroenterol, 2019, 54(2):194-203.
[21]	Labori KJ, Lassen K, Hoem D, et al. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer [Norwegian Pancreatic Cancer Trial-1 (NorPACT-1)] - study protocol for a national multicentre randomized controlled trial[J]. BMC Surg, 2017, 17(1):94.
[22]	Motoi F, Kosuge T, Ueno H, et al. Randomized phase Ⅱ/Ⅲ trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05)[J]. Jpn J Clin Oncol, 2019, 49(2):190-194.
[23]	Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial[J]. J Clin Oncol, 2022, 40(11):1220-1230.
[24]	Rangelova E, Wefer A, Persson S, et al. Surgery improves survival after neoadjuvant therapy for borderline and locally advanced pancreatic cancer: a single institution experience[J]. Ann Surg, 2021, 273(3):579-586.
[25]	Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging[J]. CA Cancer J Clin, 2017, 67(2):93-99.
[26]	Hackert T, Sachsenmaier M, Hinz U, et al. Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients[J]. Ann Surg, 2016, 264(3):457-463.
[27]	Philip PA, Lacy J, Portales F, et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT):a multicentre, open-label phase 2 study[J]. Lancet Gastroenterol Hepatol, 2020, 5(3):285-294.
[28]	Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer[J]. Ann Surg, 2015, 261(1):12-17.

Please choose a citation manager

Content to export